Camelid Nanobodies Poised to Revolutionize Antibody Therapeutics

Single-domain antibodies, or nanobodies, have recently been thrust into the spotlight as a potential treatment for COVID-19. In fact, a COVID-19 nanobody-based treatment developed by the Beroni Group, an Australian biotechnology company, is currently in preclinical testing. Even though nanobodies are only beginning to realize their therapeutic potential, they have been studied for decades.